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We investigated the genetic, phenotypic and interferon status of 46 patients from 37 
families with neurological disease due to mutations in ADAR1. The clinico-radiological 
phenotype encompassed a spectrum of Aicardi-Goutières syndrome (AGS), isolated 
bilateral striatal necrosis (BSN), spastic paraparesis with normal neuroimaging, a 
progressive spastic dystonic motor disorder, and adult-onset psychological difficulties 
with intracranial calcification. Homozygous missense mutations were recorded in five 
families. We observed a p.Pro193Ala variant in the heterozygous state in 22 of 23 
families with compound heterozygous mutations. We also ascertained 11 cases from 
nine families with a p.Gly1007Arg dominant-negative mutation, which occurred de 
novo in four patients, and was inherited in three families in association with marked 
phenotypic variability. In 50 of 52 samples from 34 patients we identified a marked 
upregulation of type I interferon stimulated gene transcripts in peripheral blood, with a 
median interferon score of 16.99 (interquartile range (IQR): 10.64 – 25.71) compared to 
controls (median: 0.93, IQR: 0.57 – 1.30). Thus, mutations in ADAR1 are associated 
with a variety of clinically distinct neurological phenotypes presenting from early 
infancy to adulthood, inherited either as an autosomal recessive or dominant trait. 





Adenosine deaminases acting on RNA (ADARs) catalyse the hydrolytic deamination of 
adenosine to inosine in double-stranded RNA, and thereby potentially alter the 
information content and structure of cellular RNAs1. ADAR1 is encoded by a single-
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copy gene that maps to human chromosome 1q21 and is present in two main isoforms 
in mammalian cells. In mice, a loss of ADAR1 activity leads to a dramatic upregulation 
of interferon-stimulated gene (ISG) expression, which is dependent on the editing 
activity of ADAR1 and specific to the interferon-inducible full-length p150 isoform of 
the protein2-4. 
 
In 2012 we reported mutations in ADAR1 to cause a phenotype consistent with the 
infantile encephalopathy Aicardi-Goutières syndrome, and demonstrated that, similar to 
the Adar1-null mouse, the mutant genotype was associated with an upregulation of type 
I interferon signalling5. Further to this, in 2014, we described both bilateral striatal 
necrosis, sometimes occurring after a trivial childhood infection, and otherwise non-
syndromic, slowly progressive spastic paraparesis associated with normal intellect to 
occur due ADAR1 dysfunction, again in association with the enhanced expression of 
type I interferon induced gene transcripts6-8. These data indicate that neurological 
disease can occur through inappropriate induction of the innate immune system by self-
derived nucleic acids.  
 
Here we present an update of our experience of screening for ADAR1 mutations, 
describing the clinical, radiological, molecular and interferon biomarker characteristics 
of a cohort of 46 patients from 37 families with neurological dysfunction due to 
mutations in ADAR1. 
 
Materials and methods 
Patients and methods 
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We ascertained clinical and molecular data through direct contact and / or via 
collaborating physicians. The study was approved by the Leeds (East) Research Ethics 
Committee (reference number 10/H1307/132), and the Comité de Protection des 
Personnes (ID-RCB / EUDRACT: 2014-A01017-40). 
 
A diagnosis of Aicardi-Goutières syndrome was suggested by characteristic clinical and 
neuroimaging features including cerebral atrophy, white matter disease and intracranial 
calcification9. Bilateral striatal necrosis was diagnosed in the context of an acute or 
subacute onset of a dystonic / rigid motor disorder associated with magnetic resonance 
imaging (MRI) features of bilateral striatal signal change with or without swelling. 
Spastic paraparesis / tetraparesis and spastic dystonia were diagnosed according to 
clinical signs, in the presence of either normal neuroimaging or mild non-specific 
changes sometimes including calcification of the basal ganglia. Assessment of the 
motor and communication status of patients over the age of 1 year was made using the 
Gross Motor Function Classification System (GMFCS)10, the Manual Ability 
Classification System (MACS)11, and the Communication Function Classification 
System (CFCS)12.  
 
Mutational analysis 
Primers were designed to amplify the coding exons of ADAR1 (Supplementary Table 1). 
Purified PCR amplification products were sequenced using BigDye terminator 
chemistry and an ABI 3130 DNA sequencer. Mutation description is based on the 
reference cDNA sequence NM_001111.4, with nucleotide numbering beginning from 
the first A in the initiating ATG codon. Variants were assessed using the in silico 
programmes SIFT (http://sift.jcvi.org) and Polyphen2 
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(http://genetics.bwh.harvard.edu/pph2/), and population allele frequencies obtained 




Whole blood was collected into PAXgene tubes, total RNA extracted using a 
PreAnalytix RNA isolation kit and RNA concentration assessed using a 
spectrophotometer (FLUOstar Omega, Labtech). Quantitative reverse transcription 
polymerase chain reaction (qPCR) analysis was performed using the TaqMan Universal 
PCR Master Mix (Applied Biosystems), and cDNA derived from 40 ng total RNA. 
Using TaqMan probes for IFI27 (Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1 
(Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2 (Hs01057264_m1), and 
SIGLEC1 (Hs00988063_m1), the relative abundance of each target transcript was 
normalized to the expression level of HPRT1 (Hs03929096_g1) and 18S 
(Hs999999001_s1), and assessed with the Applied Biosystems StepOne Software v2.1 
and DataAssist Software v.3.01. For each of the 6 probes, individual data were 
expressed relative to a single calibrator. RQ (relative quantification) is equal to 2-Ct 
i.e. the normalized fold change relative to the control data. The median fold change of 
the 6 genes compared to the median of 29 previously collected healthy controls is used 
to create an interferon score for each individual, with an abnormal interferon score 
being defined as greater than +2 standard deviations above the mean of the control 






We collected data on 46 patients from 37 families of pan-ethnic origin with either 
biallelic mutations in ADAR1 (28 families) or the single known dominant-negative 
mutation p.Gly1007Arg (nine families)(Table 1; Figure 1). In four families the 
p.Gly1007A mutation was considered to have occurred de novo, whilst in three families 
inheritance was confirmed or inferred (2 paternal half-siblings born to an unaffected 
father unavailable for testing), with somatic mosaicism recorded in one case.  In two 
families inheritance could not be determined because DNA from both parents was not 
available. We observed three distinct homozygous mutations in five families (two 
families each sharing the same mutation), in four of which the parents were knowingly 
related. All of these mutations were missense. Of 23 families with compound 
heterozygous mutations, 22 carried the p.Pro193Ala mutation on one allele. In 13 of 22 
families segregating this p.Pro193Ala substitution the second molecular lesion was a 
null or splicing variant.  
 
Clinical radiological phenotype 
Clinical radiological characteristics of all patients are summarised in Table 2, and 
characteristic radiological appearances summarised in Figure 2. Median age of disease 
onset was 14 months (range: birth – 30 years). We observed 21 and 25 affected females 
and males respectively. Although spasticity and dystonia were common features present 
in the majority of patients, clinically and radiologically distinct phenotypes could be 
defined, including classical Aicardi-Goutières syndrome (15 patients), bilateral striatal 
necrosis (16 patients), apparently isolated spastic paraparesis (one patient) / tetraparesis 
(two patients) and a progressive spastic dystonic motor disorder (seven patients). In two 
of these latter cases the initial presentation was of isolated lower limb spasticity, with a 
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dystonic component and involvement of the upper limbs only becoming evident several 
years later. Four patients demonstrated radiological features of both Aicardi-Goutières 
syndrome and bilateral striatal necrosis. The mother of a child with an Aicardi-
Goutières syndrome presentation was diagnosed at the age of 30 years with subtle 
psychological features and marked intracranial calcification. We identified three 
patients with significant neurological disease (a spastic / dystonic phenotype) in the 
absence of changes on brain imaging at presentation.  
 
Twenty five patients were considered to have demonstrated normal development prior 
to disease onset, in 18 of whom there was a history of either vaccination (four patients) 
or a notable infectious episode (14 patients) in the period shortly preceding the 
development of clinical signs (Figure 3A). A number of patients experienced a rapid 
onset of dystonia / spasticity and loss of skills, with two patients being admitted to 
intensive care due to severe dystonic crisis. Others exhibited a more slowly progressive 
onset over weeks or months. Definite clinical progression beyond the initial 
presentation was recorded in 16 cases. Nine patients are deceased, between the ages of 
10 months and 19 years, six of whom had early-onset disease consistent with Aicardi-
Goutières syndrome.  
 
An assessment of gross motor function, manual ability and communication status at last 
contact was made in 45 patients, of whom 27 were recorded to have none of any 
purposeful gross motor, hand and communication function (score of 5 on all three 
scales)(Figure 3B). Five patients were able to walk with no or some support (GMFCS I 
– III). Eleven patients were capable of effective sender and receiver communication 
(CFCS I – III). Although formal testing was not undertaken, seven patients were 
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considered to have normal intellectual function.  
 
Five patients were reported to demonstrate hypo / hyperpigmentation consistent with 
dyschromatosis symmetrica hereditaria 1 (DSH), and two patients were described with 
chilblain-like vasculitic lesions. Four patients were documented with autoimmune 
haemolytic anaemia. Glaucoma was not recorded in any patient.  
 
Interferon status 
We derived 52 interferon scores from 34 patients, 50 of which were abnormal, with a 
median interferon score across the group of 16.99 (interquartile range (IQR): 10.64 – 
25.71) compared to controls (median: 0.93, IQR: 0.57 – 1.30)(Figure 4). Positive scores 
were observed up to 25 years after disease onset. We also tested 20 interferon scores 
from 16 parental carriers of a recessive mutation in ADAR1. Two samples from seven 
parents heterozygous for the recurrent p.Pro193Ala mutation demonstrated a positive 
interferon score, versus six samples from nine parents carrying a different mutation 
(Supplementary Figure 1). 
 
Discussion 
In 2012, ADAR1 mutations were described in the context of the early-onset 
encephalopathy Aicardi-Goutières syndrome, associated with the presence of 
intracranial calcification, white matter disease and severe developmental delay5. 
Subsequently, in 2014, mutations in ADAR1 were also shown to underlie cases of 
apparently non-syndromic bilateral striatal necrosis, and of isolated spastic paraparesis 
with normal neuroimaging6,7. Here we confirm these associations, thus emphasising the 
need to consider ADAR1-related disease in a number of distinct clinical scenarios 
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triggering different investigative algorithms. Furthermore, we now describe a patient 
with a dominant-negative mutation in ADAR1 demonstrating an adult-onset phenotype 
evocative of ‘idiopathic’ basal ganglia calcification characterised by intracranial 
calcification and subtle psychological disturbance. Our clinical and radiological 
findings highlight the propensity of ADAR1-related disease to incur basal ganglia 
dysfunction, and the value of basal ganglia calcification, frequently only appreciated on 
computed tomography, as a diagnostic indicator. More generally, mutations in ADAR1 
should be thought of in the context of a motor disorder characterised by spasticity and 
dystonia. The onset of disease can occur after a period of normal development, 
sometimes associated with a rapid loss of skills, or a much slower progression over 
many years. Assessments using the GMFCS, MACS and CFCS rating scales indicate 
that disease outcome in the cases that we have ascertained is frequently severe. It is of 
note that we observed cases with completely preserved intellect + / - normal 
neuroimaging in the face of significant motor disability.  
 
Our own research focus is biased towards the ascertainment of paediatric disease. 
However, Tojo et al. described a female patient with the dominant-negative 
p.Gly1007Arg mutation, presenting at age 17 years with gait disturbance and dystonic 
posturing of the legs, who experienced intellectual deterioration from 21 years of age, 
and became wheelchair bound a year later13. Together with our observation of an adult 
female whose clinical phenotype only became evident at age 30 years, it is clear that 
later onset disease can occur due to ADAR1 deficiency. This latter case also illustrates 
the significant intra-familial variability which can be seen in association with ADAR1 
dysfunction, the mother presenting in adulthood with subtle psychological disturbance, 
whilst her son experienced a devastating early-onset encephalopathy. 
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ADAR1-related neurological disease can be inherited as either an autosomal recessive 
or autosomal dominant trait. We observed homozygosity for a missense mutation in five 
of 28 families segregating recessive disease. As previously suggested, the absence of 
patients with homozygous null mutations indicates that, as for the Adar1-null mouse, 
complete loss of ADAR1 protein activity is likely embryonic lethal5. Our molecular 
data reveal a remarkably high frequency of the p.Pro193Ala substitution, seen in 22 of 
23 families with compound heterozygous molecular lesions in ADAR1. This mutation, 
which is recorded on 602 of 282,636 alleles in the gnomAD database, was not observed 
in the homozygous state in our cohort. That this variant was seen in combination with a 
null mutation in 13 families suggests that homozygosity for the p.Pro193Ala allele leads 
to a milder, later-onset or distinct phenotype not ascertained here, or may not be 
associated with disease. Perhaps of note, the gnomAD database includes one individual 
homozygous for this mutation. Finally, our molecular data highlight the dominant-
negative p.Gly1007Arg mutation, which can occur de novo, or be inherited with 
variable expression and / or non-penetrance at least into mid-adult life. The proximity of 
Gly1007 to the backbone of its RNA ligand, and the possibility for an arginine residue 
to make polyvalent interactions there, suggests a mechanism whereby Arg1007 might 
bind more tightly to RNA and thus act as a competitive inhibitor of wild-type protein, 
whilst being itself catalytically inactive14. In keeping with this model, we previously 
demonstrated that a plasmid expressing Gly1007Arg showed stronger inhibition of 
wild-type ADAR1 than equivalent amounts of a plasmid expressing catalytic inactive 
ADAR15. 
 
More than 130 different ADAR1 mutations have been documented in patients with DSH, 
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an autosomal-dominant disorder characterised by the childhood onset of hypopigmented 
and hyperpigmented macules on the face and dorsal aspects of the extremities15. DSH 
has only very rarely been reported outside of Japan and China, and even within 
identified families a marked variability in expression is well recognised. In our series, 
five patients were noted to demonstrate pigmentary lesions consistent with DSH. The 
frequent observation of stop and frameshift variants in DSH indicates 
haploinsufficiency as the likely molecular pathology, consistent with the recent 
confirmation of our previous suggestion that two individuals with DSH would be at one 
in four risk of a pregnancy with ADAR1-related neurological disease16.  
 
Loss-of-function mutations in ADAR1 have been classified within the so-called type I 
interferonopathy grouping, a novel set of inborn errors of immunity where it is proposed 
that an upregulation of type I interferon signalling is central to disease pathogenesis17,18. 
The Aicardi-Goutières syndrome phenotype can arise due to mutations in any one of 
seven genotypes within this grouping (AGS1-7: TREX1, RNASEH2A, RNASEH2B, 
RNASEH2C, SAMHD1, ADAR1 and IFIH1), and apparently isolated spastic paraparesis 
has been reported in patients mutated in three of these genes (RNASEH2B, ADAR1 and 
IFIH1). In contrast, in an overview of 374 patients from 299 families with mutations in 
AGS1-7, bilateral striatal necrosis, the most frequently ascertained phenotype in the 
current series, was only recorded in the context of ADAR1-related disease, suggesting 
discrete factors relevant to gene / protein expression and disease mechanism consequent 
upon ADAR1 dysfunction19. Possibly also reflective of this apparent specificity, in 
comparison to other genotypes, is the frequency of clinical progression, and the low risk 
of developing glaucoma and chilblain-like lesions (since we recorded no examples of 
the former, and only two cases of the latter in our cohort).  
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The consistent finding of a positive interferon signature in peripheral blood in the series 
of patients reported here indicates the potential utility of this biomarker as a screening 
test for ADAR1-related disease, for the interpretation of ADAR1 genetic sequence 
variants of uncertain significance, and in the possible monitoring of treatment efficacy 
as anti-interferon therapies are developed20,21. We emphasise that the interferon 
signature remains elevated many years after disease onset, providing evidence of 
ongoing pathology. ADAR1 is expressed throughout the brain including the basal 
ganglia (http://www.brain-map.org), and it has been shown that a loss of ADAR1 
renders cells more susceptible to apoptosis following stress, including infection22. We 
cannot rule out the possibility that the occurrence of fevers prior to frank neurological 
regression represents a prodrome in some cases. However, a history of vaccination or an 
apparently discrete infectious episode in several patients considered to be completely 
developmentally normal prior to disease onset, of whom 12 demonstrated bilateral 
striatal necrosis on neuroimaging, raises the possibility that the acute degeneration of 
striatal tissue seen in many patients with ADAR1 mutations might relate to a rapid 
induction of apoptosis triggered by viral infection / metabolic stress. Beyond this 
possibility, there is strong evidence that interferon is a neurotoxin23-27, and we consider 
it likely that inappropriate and chronic exposure to type I interferons may be directly 
relevant to the ADAR1-related neurological phenotypes described here, perhaps 
induced by dsRNA species which are normally edited by ADAR1, thereby rendering 
them as immunology inert / marking them as self1,3,4,28. These observations highlight the 
potential utility of treatments for ADAR1-related disease, which recent data suggest 
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Figure 1. Schematic of ADAR1 gene showing mutations (according to protein 
nomenclature) ascertained in the present study. Missense and nonsense mutations are 
annotated above and below respectively. Numbers in brackets indicate the number of 
families in which each mutation was observed. † indicates mutation acting as a 
dominant negative. 
 
Figure 2. Characteristic neuroradiological features of ADAR1-related disease. A and D 
are axial T2 images of AGS251, presenting at 9 months of age with bilateral striatal 
necrosis following varicella zoster infection, showing characteristic high signal and 
swelling of head of caudate and putamen (A). Follow up (D) at 35 months shows 
persisting signal change and shrinkage of caudate and putamen. Images B and E are 
from AGS150, a 10 year old child presenting with an Aicardi-Goutières syndrome 
phenotype. T2 axial MR (B) shows cerebral atrophy with mildly increased signal in 
white matter. CT (E) shows dense bilateral globus pallidus calcification. Image C is of a 
patient presenting with an Aicardi-Goutières syndrome phenotype (AGS810_P1). T2 
axial MR at 5 years (C) shows marked cerebral atrophy, white matter high signal and 
signal change and shrinkage of the putamen. CT scan of his mother (F)(AGS810_P2) 
aged 34 years shows dense calcification of globus pallidus, head of caudate and deep 
frontal white matter. Her MR (not shown) was normal. 
 
Figure 3. Age at presentation and associated disability. (A) Age at presentation in 
patients developing disease after a period of clearly normal development. (B) 
Assessment of gross motor function, manual ability and communication status in living 
patients with mutations in ADAR1 over 1 year of age.  
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Figure 4. Interferon score data in ADAR1-mutated patients and controls. Summary of 
interferon score data in ADAR1-mutated patients and controls (A), and in ADAR1-
mutated patients by age (B). Red circles indicate results above +2 SD of the mean of 29 
controls (= 2.466, considered ‘positive’). Solid horizontal lines indicate median value of 
ADAR1-mutated and control groups. Dotted line indicates positive / negative boundary 
(2.466) of interferon score. 
